Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster

Ítems similars

• Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months
  per: Russell, FM, et al.
  Publicat: (2011)
• Opsonophagocytic Activity Following a Reduced Dose 7-valent Pneumococcal Conjugate Vaccine Infant Primary Series and 23-valent Pneumococcal Polysaccharide Vaccine at 12 Months of Age
  per: Russell, FM, et al.
  Publicat: (2010)
• Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children following a reduced dose pneumococcal conjugate vaccine primary series in infancy
  per: Boelsen, Laura K., et al.
  Publicat: (2015)
• Safety and Immunogenicity of the 23-Valent Pneumococcal Polysaccharide Vaccine at 12 months of age, following One, Two, or Threes Doses of the 7-valent Pneumococcal Conjugate Vaccine in Infancy
  per: Russell, F.M., et al.
  Publicat: (2010)
• Immunogenicity Following One, Two, or Three Doses of the 7-valent Pneumococcal Conjugate Vaccine
  per: Russell, FM, et al.
  Publicat: (2009)